Digest Network Come funziona
Network
/
Società
Ta
Non verificato

Takeda Pharmaceutical Company Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

54 comunicati stampa

Guarda tutti i comunicati
16/07/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
12/07/2026
Mercato del lavoro
Industria
Medicina - Varie
Attrezzature medico-sanitarie
Sanità
Management
Biotecnologia
Salute
Farmaceutica
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
24/06/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Oncologia
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
15/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
11/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
09/06/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
13/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Oncologia
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
04/05/2026
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
28/03/2026
Eventi
Industria
Web e Social Network
Telefonia e Varie
Salute
Medicina - Varie
Sanità
Scienza
Farmaceutica
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0